REGENXBIO Inc. (RGNX) SEC Filings & Earnings Calls

Loss of a director with CEO experience at another company may reduce board expertise, but transition appears orderly.

“Director resignation due to new CEO role; no disagreement with company.”

Litigation resolved, but covenant not to sue limits future patent enforcement against Sarepta's AAVrh74 products.

“covenant not to sue for future claims relating to any Sarepta gene therapy product that uses an AAVrh74-based capsid” · word for word

Board refreshment with independent director; no material risk identified.

“Resignations not due to disagreements; new director is independent.”

FDA clinical hold on RGX-121 due to asymptomatic spine MRI findings; BLA resubmission delayed indefinitely.

“FDA placed clinical hold on RGX-121 following asymptomatic spine MRI findings in five participants; company does not expect to resubmit BLA in near term.”

Potential for similar findings in other gene therapy programs using same capsid or route of administration.

“Company believes findings are unique and limited to Hunter Syndrome program, but risk of broader implications exists.”

AAV vector integration safety risk

“Final analysis of the resected tumor was conducted by an independent third-party lab and, as previously reported, detected an AAV vector genome integration event associated with overexpression of a PLAG1.” · word for word

Zolgensma patent expiration revenue decline

“Zolgensma royalties for the second quarter of 2026 were $1.8 million, a decrease of $16.7 million from the second quarter of 2025, which was primarily attributable to the expiration of licensed patents in the United States in January 2026.” · word for word

Dependence on collaboration partners

“Our revenues are concentrated among a low number of licensees and collaborators and the arrangements are terminable at the option of the counterparty.” · word for word

Dependence on clinical trial outcomes and regulatory approvals for pipeline assets

“Multiple near-term catalysts including BLA submission and pivotal data readouts; any delays or negative results could impact stock.”

Dilution risk from equity offering

“10,003,889 shares of common stock and pre-funded warrants for 1,111,111 shares”

Going Concern Risk

“These conditions raise substantial doubt about our ability to continue as a going concern within 12 months from the issuance date of our consolidated financial statements for the three months ended March 31, 2026.” · word for word

FDA Rejection of RGX-121 BLA

“In February 2026, we announced that the FDA issued a Complete Response Letter (CRL) for the RGX-121 BLA.” · word for word

Safety Signal in RGX-111 (Neoplasm)

“In January 2026, we announced that the FDA placed the RGX-111 program on partial clinical hold following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in the Phase I/II study.” · word for word

Patent Expiration Impact on Royalties

“In mid-January 2026, licensed patents for Zolgensma under the Novartis License expired in the United States.” · word for word

GSK Settlement Charge

“a non-recurring charge of $10.0 million in the first quarter of 2026 related to a settlement with GlaxoSmithKline LLC (GSK) to resolve a dispute over sublicense fee obligations” · word for word

Settlement resolves past dispute but future sublicense fee allocation methodology remains unchanged, leaving potential for future disagreements.

“The Company will continue to pay GSK amounts received from sublicensees pursuant to existing sublicense agreements, utilizing the Company’s existing allocation methodology.” · word for word

FDA CRL for RGX-121

“In February 2026, we announced that the FDA issued a Complete Response Letter (CRL) for the RGX-121 BLA.” · word for word

Clinical hold for RGX-111 due to tumor signal

“In January 2026, we announced that the FDA placed the RGX-111 program on clinical hold following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in the Phase I/II study.” · word for word

Dependence on collaborations

“Our revenues are concentrated among a low number of licensees and collaborators and the arrangements are terminable at the option of the counterparty.” · word for word

Regulatory approval risk for lead pipeline asset RGX-121; potential loss of revenue opportunity and R&D impairment.

“FDA CRL for RGX-121; company plans to request Type A meeting and resubmit BLA.”

Clinical hold on two key pipeline programs (RGX-111 and RGX-121) creates significant regulatory and development risk

“FDA placed clinical hold on both RGX-111 (MPS I) and RGX-121 (MPS II) trials”

Potential for stock price decline and loss of investor confidence

“Clinical holds on late-stage gene therapy programs typically result in significant market value destruction”

Regulatory approval uncertainty for RGX-121 and RGX-202

“There can be no assurance, however, that our resubmitted BLA will result in approval.”

High interest expense from royalty monetization liabilities

“Interest expense increased by $12.3 million, from $0.8 million for the three months ended September 30, 2024 to $13.2 million for the three months ended September 30, 2025.” · word for word

Concentration of revenue in few licensees

“Our revenues are concentrated among a low number of licensees and collaborators and the arrangements are terminable at the option of the counterparty.” · word for word

Clinical and regulatory risk; dependence on FDA approvals

“Multiple programs pending FDA decisions; no approved products yet”